Bonnie Ogden, PA
Medical · Chesterfield, MINPI 1144254046
Payments from drug & device makers
Across 198 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$538
- Lilly USA, LLC$420
- AbbVie$411
- Novo Nordisk$368
- Amgen$231
- Pfizer$161
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,16198%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $538 |
| Lilly USA, LLC | 28 | $420 |
| AbbVie | 26 | $411 |
| Novo Nordisk | 24 | $368 |
| Amgen | 15 | $231 |
| Pfizer | 9 | $161 |
| GSK | 8 | $115 |
| AstraZeneca | 7 | $109 |
| Corcept Therapeutics | 7 | $96 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $90 |
| Astellas Pharma US Inc | 4 | $74 |
| Bayer | 4 | $66 |
| Currax Pharmaceuticals LLC | 3 | $65 |
| Nestle Healthcare Nutrition Inc. | 4 | $61 |
| Alk-abello, Inc | 2 | $38 |
| Exact Sciences | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Novartis | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Johnson & Johnson | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific | 1 | $18 |
| Electromed, Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Gilead | 1 | $15 |
| Abbott | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$3,211 in reported general payments places this provider in the 80th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $53,350 |
| OzempicSemaglutide | 32 | $44,196 |
| EliquisApixaban | 29 | $40,814 |
| JardianceEmpagliflozin | 19 | $23,908 |
| XareltoRivaroxaban | 22 | $20,891 |
| GlyxambiEmpagliflozin/Linagliptin | 20 | $18,920 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $17,823 |
| MyrbetriqMirabegron | 12 | $12,452 |
| Emgality PenGalcanezumab-Gnlm | 13 | $10,012 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,854 |
| Olmesartan Medoxomil | 83 | $2,334 |
| Metoprolol Succinate | 116 | $2,287 |
| Atorvastatin Calcium | 152 | $2,055 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 33 | $1,907 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $420 | $53,35038 claims |
| Novo NordiskOzempic | $368 | $44,19632 claims |
| Boehringer IngelheimJardiance, Glyxambi | $538 | $42,82839 claims |
| PfizerEliquis | $161 | $40,81429 claims |
| Johnson & JohnsonXarelto | $27 | $20,89122 claims |
| GSKTrelegy Ellipta | $115 | $17,82321 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $12,45212 claims |
| AbbVieSynthroid | $411 | $1,24716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 755 medical providers in Michigan.
Other medical in Chesterfield
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.